QTTB Stock Price, Chart, Stats & News
Q32 Bio Inc (QTTB) does not currently pay a dividend.
QTTB chart
Fundamentals
Gross margin | 99.66% |
Operating margin | 31.46% |
Pretax margin | 55.49% |
Net margin | 55.49% |
Effective tax rate | – |
ROA | 48.27% |
ROE | 1630.23% |
D/E | 0.27x |
Interest coverage ratio | 15.37x |
QTTB valuation
P/E | 7.36x |
P/S | 1.66x |
P/B | 2.17x |
P/CF | -2.72x |
P/FCF | -2.66x |
P/OCF | -2.72x |
PEG | 0.02x |
EV multiple | 6.62x |
About
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis.
Similar securities
Based on sector and market capitalization
